Multiple Myeloma Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
Select
11-0685 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma
11506A Collection of Bone Marrow Samples from Patients with Multiple Myeloma who Already are Undergoing a Bone Marrow Biopsy and Aspirate
10-064-B Molecular characterization of hematopoietic malignancies
11-0445 A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Select
12-0078 A Phase I Study of the Combination of Panobinostat and Carfilzomib for Patients with Relapsed and Refractory Multiple Myeloma
Select
IRB12-1088 Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma
Select
IRB12-1466 A Phase 3, Randomized, Controlled, Open- label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Select
12-1725 Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment with Carfilzomib, Lenalidomide and Low dose Dexamethasone (CRd) in Transplant Candidates with Newly Diagnosed, Multiple Myeloma (MM) Requiring Systemic Chemotherapy
Select
IRB12-1907 A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma
Select
IRB12-2150 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients with Hematologic Malignancies
Select
IRB14-0042 Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0364 Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed or Refractory Multiple Myeloma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.